Baylor Scott & White Health is a healthcare system based in Dallas, Texas, United States. Formed in 2013 from the merger of Scott & White Health with Baylor Healthcare System, it became the largest non-profit healthcare system in Texas, and one of the largest in the country. Its network contains over 50 hospitals and more than 800 patient care sites.
Moyamoya disease (MMD) is a progressive cerebrovascular disorder characterized by arterial stenosis and compensatory neovascularization, but its upstream drivers remain poorly defined. Here, we identify Bifidobacterium pseudocatenulatum (B. pseudocatenulatum), a traditionally probiotic species, as a context-dependent pathobiont. Integrated metagenomic and metabolomic analyses revealed enrichment of B. pseudocatenulatum in MMD, closely associated with elevated microbial-derived histamine and serotonin. In mice, chronic oral administration of B. pseudocatenulatum disrupted intestinal barrier integrity and increased gut microbial production and systemic levels of histamine and serotonin. These changes were accompanied by systemic inflammation and activation of angiogenic pathways, which together promoted MMD-relevant cerebrovascular remodeling in experimental models. Notably, direct administration of histamine or serotonin to mice reproduced key MMD-like vascular phenotypes, supporting the conclusion that these microbial metabolites are sufficient to induce selected MMD-relevant vascular changes in experimental models. Our findings propose a microbial–metabolite–vascular axis and suggest that the role of specific Bifidobacterium strains may be more nuanced than previously recognized. These results provide a mechanistic framework for understanding the gut–brain axis in neurovascular pathology and nominate the microbiome and its metabolic products as potential targets for non-invasive diagnostics and precision therapeutic interventions in MMD.
The Society of Thoracic Surgeons (STS) 2026 Expert Consensus Pathway on Robotic Cardiac Training outlines principles for the safe initial introduction and subsequent expansion of robotic cardiac programs. The 25-year history of robotic cardiac surgery has established safety and efficacy while providing multiple innovations. There is currently a unique opportunity to coalesce best practices and evidence to inform a recent global surge in interest in incorporating robotic techniques into standard cardiac surgical practice. This consensus is a collaborative effort between the STS Workforce on Evidence Based Surgery, the STS Robotic Cardiac Surgery Taskforce, and multinational leaders in robotic cardiac surgery that aims to standardize initial core principles of preparatory elements, followed by 4 phases of robotic cardiac training to proceed from program commencement to mastery.
The gut-brain axis is increasingly recognized as a critical contributor to Parkinson's disease (PD) pathogenesis, yet the therapeutic impact of microbiota modulation remains unclear due to lack of clinical trials in drug-naïve patients. We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the safety, tolerability, and efficacy of repeated donor fecal microbiota transplantation (dFMT) in de novo PD. FMT was administered for seven days (200 mL on days 1-3; 50 mL on days 4-7) per 4-week cycle. Seventy-two patients were randomized 1:1 to receive dFMT or autologous FMT (aFMT), and 66 completed the trial. At 35 weeks, the dFMT group showed significant improvement in motor symptoms (mean change in Unified Parkinson's Disease Rating Scale [UPDRS] III: -3.8 vs. +0.1; p = 0.0001) and a substantially greater reduction in constipation severity (dFMT vs. aFMT: -6.5 vs. -0.7; p < 0.0001), accompanied by improved quality-of-life scores. Microbiome profiling revealed greater similarity to donor composition and a marked reduction in Escherichia-Shigella, correlating with decreased colonic α-synuclein aggregation (r = 0.3775, p = 0.0277), supporting a gut-brain mechanistic link. Biochemical analyses showed elevated fecal dopamine and 3,4-dihydroxyphenylacetic acid levels, while histological assessments demonstrated strengthened epithelial barrier integrity with increased E-cadherin expression. All adverse events were mild and self-limited; no serious treatment-related events were observed. These findings demonstrate that repeated dFMT is safe, well tolerated, and yields clinically meaningful motor and gastrointestinal improvements in drug-naïve PD, providing integrated mechanistic and clinical evidence that microbiota-targeted modulation represents a promising nonpharmacologic therapeutic strategy for neurodegenerative disease. Trial registration: Chinese Clinical Trial Registry, ChiCTR2200064151.
Cardiac amyloidosis is an infiltrative cardiomyopathy caused by extracellular deposition of amyloid fibrils, most commonly from immunoglobulin light chain (AL) or transthyretin (ATTR) proteins. Cardiac involvement dictates prognosis, with restrictive physiology, diastolic dysfunction, and conduction disease leading to progressive heart failure. Management of heart failure in cardiac amyloidosis differs fundamentally from conventional heart failure strategies. Due to preload dependence, autonomic dysfunction, and poor tolerance of standard therapies, treatment focuses on cautious volume control using low-dose diuretics, while β-blockers and ACE inhibitors, are used sparingly. Mineralocorticoid receptor antagonists are generally well tolerated and commonly used, with monitoring for hyperkalemia and renal dysfunction. Disease-specific therapy has revolutionized outcomes: daratumumab-based chemotherapy in AL amyloidosis achieves rapid and deep hematologic responses, improving cardiac biomarkers, imaging parameters, and survival. In the ATTR-subtype, transthyretin stabilizers and silencers significantly reduce mortality, cardiovascular hospitalizations, and functional decline, especially when initiated early. Atrial fibrillation and conduction disease are common; anticoagulation is indicated irrespective of CHA₂DS₂-VASc score. Ιmplantable cardioverter-defibrillator and cardiac resynchronization therapy are reserved for standard indications, with limited survival benefit. Inotropes serve as palliative or bridge therapy in end-stage disease, while transplantation remains viable in selected patients with controlled systemic disease. Emerging TTR stabilizers, gene silencers, and fibril-clearing antibodies may further transform prognosis. Advances in imaging, digital monitoring, and multidisciplinary care aim to enhance early detection and individualized management. Timely diagnosis, evidence-based therapy, and coordinated multidisciplinary care are essential to optimize survival and quality of life in cardiac amyloidosis.